November 20th 2024
The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
FDA Clears Mini Transesophageal Echocardiography Ultrasound Transducer
January 31st 2024Reportedly providing enhanced imaging of structural heart disease, the minimally invasive X11 4t Mini 3D TEE ultrasound transducer facilitates use of the technology in smaller pediatric patients as well as high-risk ICU patients.
FDA Grants De Novo Clearance for Ultrasound-Based Liver Tumor Ablation Software
January 8th 2024The BioTraceIO software reportedly facilitates visualization of liver tumor ablation procedures based on real-time ultrasound imaging and provides superior post-op estimates of ablation zone volume in comparison to computed tomography.
Can ChatGPT and Bard Bolster Decision-Making for Cancer Screening in Radiology?
December 21st 2023In a study examining the potential of the large language models ChatGPT-4 and Bard to follow ACR Appropriateness Criteria for breast cancer, lung cancer, ovarian cancer and colorectal cancer screening, researchers noted “impressive accuracy in making radiologic clinical decisions.”
Samsung Debuts New Ultrasound Modality Geared Toward Women's Health and Urology
November 15th 2023Combining enhanced imaging capabilities, workflow efficiencies and artificial intelligence (AI)-enabled technology to improve the diagnosis and management of health conditions in women, Samsung has launched the V6 ultrasound system.
Outpatient Reimbursement to Increase 65 Percent for EchoGo Heart Failure Platform in 2024
November 8th 2023Reimbursement for use of the artificial intelligence (AI)-powered EchoGo Heart Failure platform in hospital outpatient settings for Medicare and Medicaid patients is expected to increase from $99.81 to $284.88 in 2024.
Study Links PTSD to Higher Carotid Atherosclerosis and White Matter Hyperintensity in Midlife Women
November 6th 2023Ultrasound and MRI findings from a new study suggest that greater carotid atherosclerosis and elevated white matter hyperintensities among women with the APOEe4 genotype, a strong risk factor for Alzheimer’s disease, are associated with increased PTSD symptoms in midlife women.